Market capitalization | $19.18b |
Enterprise Value | $17.65b |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 5.70 |
P/S ratio (TTM) P/S ratio | 6.19 |
P/B ratio (TTM) P/B ratio | 6.22 |
Revenue growth (TTM) Revenue growth | 71.01% |
Revenue (TTM) Revenue | $3.10b |
As a Free StocksGuide user, you can view scores for all 6,908 stocks worldwide.
31 Analysts have issued a BeiGene Ltd. Sponsored ADR forecast:
31 Analysts have issued a BeiGene Ltd. Sponsored ADR forecast:
Dec '23 | |
Current assets | 4,203 4,203 |
Fixed assets | 1,602 1,602 |
Total Assets | 5,805 5,805 |
Dec '23 | |
Equity | 3,537 3,537 |
Debt capital | 2,234 2,234 |
Total Capital | 5,771 5,771 |
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
BeiGene Ltd. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. It focuses on Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317), and Pamiparib (BGB-290). The company was founded by Xiao Dong Wang and John V. Oyler on October 28, 2010 and is headquartered in Beijing, China.
Head office | Cayman Islands |
CEO | John Oyler |
Employees | 10,000 |
Founded | 2010 |
Website | www.beigene.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.